CIK 0001124105 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 116.6 M | 113.5 M | 102.3 M |
| Net income (USD) | 9.9 M | -85.5 M | 4.3 M |
| Diluted EPS (USD/shares) | 0.02 | -1.41 | 0.03 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-01 | 8-K | 8-K items 7.01,9.01 | 2026-09-01 |
| 2026-08-27 | S-8 | S-8 | |
| 2026-08-26 | 8-K | 8-K items 7.01,9.01 | 2026-08-26 |
| 2026-08-07 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-07 | 8-K | 8-K items 2.02,9.01 | 2026-08-07 |
| 2026-08-04 | 4 | FORM 4 | 2026-08-03 |
| 2026-08-04 | 4 | FORM 4 | 2026-08-03 |
| 2026-08-04 | 3 | FORM 3 | 2026-08-01 |
| 2026-08-04 | 3 | FORM 3 | 2026-08-01 |
| 2026-08-03 | EFFECT | EFFECT items ,, | |
| 2026-07-16 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-07-10 |
| 2026-07-15 | 8-K/A | 8-K/A items 2.02,9.01 | 2026-05-04 |
| 2026-07-13 | S-3/A | S-3/A | |
| 2026-06-30 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-30 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-30 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-30 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-30 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-30 | 4 | FORM 4 | 2026-06-10 |
| 2026-06-23 | S-3 | S-3 | |
| 2026-06-22 | 4 | FORM 4 | 2026-06-09 |
| 2026-06-16 | 8-K | 8-K items 5.07 | 2026-06-10 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-11 |
| 2026-06-11 | 4 | FORM 4 | 2026-06-09 |
| 2026-06-10 | 4 | FORM 4 | 2026-06-08 |
Forms on file (last 1,000): 4 333, 8-K 212, 3 42, 10-Q 39, SC 13G/A 39, SC 13D/A 37, SC 13G 34, DEFA14A 26. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=GYRE (0.002 USD), /gw/filings/filings?ticker=GYRE&form=8-K, /gw/filings/facts?ticker=GYRE&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange